本文選題：人參皂苷 + 鼻咽癌��； 參考：《安徽醫(yī)科大學(xué)》2015年碩士論文

【摘要】：目的放療是鼻咽癌患者治療的首選方案,但放療在殺傷腫瘤細(xì)胞的同時(shí)也會(huì)對(duì)機(jī)體免疫功能造成損傷。人參皂苷(ginsenosidess,GS)作為人參的主要有效成分具有顯著的免疫增強(qiáng)作用。本研究分別采用人參皂苷單體Rg3、Rg1、Rb1體外刺激鼻咽癌放療患者外周血淋巴細(xì)胞,旨在探討不同人參皂苷體外對(duì)鼻咽癌放療患者外周血淋巴細(xì)胞的免疫調(diào)節(jié)作用及其機(jī)制。方法選取鼻咽癌并接受放療患者共100例為研究對(duì)象,按隨機(jī)數(shù)字表法分為Control組、Rg3組、Rg1組、Rb1組,每組25例。放療結(jié)束后,分離各組患者外周血淋巴細(xì)胞。按分組不同加入不同刺激物,Control組分別加入終濃度為1mg/L、10mg/L、100mg/L的DMSO,Rg3組分別加入終濃度為1mg/L、10mg/L、100mg/L的人參皂苷單體Rg3,Rg1組分別加入終濃度為1mg/L、10mg/L、100mg/L的人參皂苷單體Rg1、Rb1組分別加入終濃度為1mg/L、10mg/L、100mg/L的人參皂苷單體Rb1。采用MTT法檢測(cè)淋巴細(xì)胞增殖,流式細(xì)胞儀檢測(cè)淋巴細(xì)胞亞群及膜表面分子表達(dá),間接ELISA法檢測(cè)Ig G、Ig M抗體水平及Th1/Th2細(xì)胞因子表達(dá)。結(jié)果:(1)人參皂苷單體Rg3、Rg1、Rb1處理鼻咽癌放療患者外周血淋巴細(xì)胞72h后,可顯著促進(jìn)Con A及LPS誘導(dǎo)的淋巴細(xì)胞增殖,與Control組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),且呈顯著劑量依賴性;Rg3組促淋巴細(xì)胞增殖作用顯著優(yōu)于Rg1組和Rb1組(P0.05);Rg1組與Rb1組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。(2)人參皂苷單體Rg3、Rg1、Rb1處理鼻咽癌放療患者外周血淋巴細(xì)胞72h后,可顯著上調(diào)淋巴細(xì)胞亞群CD4+比例、CD4+/CD8+比值,同時(shí)顯著下調(diào)CD8+比例,與Control組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),且呈顯著劑量依賴性;Rg3組作用顯著優(yōu)于Rg1組和Rb1組(P0.05);Rg1組與Rb1組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。(3)人參皂苷單體Rg3、Rg1、Rb1處理鼻咽癌放療患者外周血淋巴細(xì)胞72h后,可顯著上調(diào)外周血T淋巴細(xì)胞表面CD3+/HLA-DR+和B細(xì)胞表面CD19+/CD69+表達(dá)水平,與Control組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),且呈顯著劑量依賴性;Rg3組作用顯著優(yōu)于Rg1組和Rb1組(P0.05);Rg1組與Rb1組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。(4)人參皂苷單體Rg3、Rg1、Rb1處理鼻咽癌放療患者外周血淋巴細(xì)胞72h后,可顯著促進(jìn)外周血淋巴細(xì)胞Ig G、Ig M抗體分泌,與Control組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),且呈顯著劑量依賴性;Rg3組作用顯著優(yōu)于Rg1組和Rb1組(P0.05);Rg1組與Rb1組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。(5)人參皂苷單體Rg3、Rg1、Rb1處理鼻咽癌放療患者外周血淋巴細(xì)胞72h后,可顯著上調(diào)外周血淋巴細(xì)胞IL-2表達(dá),同時(shí)下調(diào)IL-6表達(dá),與Control組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),且呈顯著劑量依賴性;Rg3組作用顯著優(yōu)于Rg1組和Rb1組(P0.05);Rg1組與Rb1組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:人參皂苷Rg3、Rg1、Rb1可顯著增強(qiáng)鼻咽癌放療患者外周血淋巴細(xì)胞增殖能力、抗原遞呈能力,糾正放療所致淋巴細(xì)胞亞群比例失衡及Th1/Th2免疫漂移,提高機(jī)體Ig G、Ig M抗體水平,且Rg3作用顯著優(yōu)于Rg1及Rb1。提示人參皂苷Rg3、Rg1、Rb1可作為免疫增強(qiáng)劑潛在性的拮抗鼻咽癌放療所致的免疫抑制。
[Abstract]:Radiotherapy is the preferred solution to treatment of nasopharyngeal carcinoma, but the radiation would damage the immune function in tumor cells at the same time. Ginsenoside (ginsenosidess, GS) as the main active ingredient of ginseng has significantly enhanced the immunity. This study were collected by ginsenoside Rg3, Rg1, Rb1 were stimulated in vitro radiotherapy of peripheral blood lymphocytes, immune was to investigate the effects of Ginsenoside in vitro on nasopharyngeal carcinoma patients peripheral blood lymphocyte regulation and its mechanism. Methods the nasopharyngeal carcinoma radiotherapy and 100 patients as the research object, randomly divided into Control group, Rg3 group, Rg1 group, Rb1 group, 25 cases in each group at the end of radiotherapy, peripheral blood lymphocytes were separated from patients with different. By grouping with different stimuli, group Control as the concentration of 1mg/L, 10mg/L, 100mg/L, DMSO, Rg3 group As the concentration of 1mg/L, 10mg/L, ginsenoside Rg3 100mg/L, group Rg1 as the concentration of 1mg/L, 10mg/L, ginsenoside Rg1 100mg/L, group Rb1 as the concentration of 1mg/L, 10mg/L, ginsenoside Rb1. 100mg/L MTT method was used to detect the expression of lymphocyte proliferation, flow cytometry cells detected by lymphocyte subsets and membrane surface molecules, detection of Ig G by indirect ELISA, the antibody level of M expression of Ig and Th1/Th2 cytokines. Results: (1) ginsenoside Rg3, Rg1, Rb1 in patients with nasopharyngeal carcinoma after radiotherapy of peripheral blood lymphocytes after 72h, Con and A can significantly promote LPS induced the lymphocyte proliferation, compared with the Control group. The difference was statistically significant (P0.05), and a significant dose dependence; group Rg3 lymphocyte proliferation was significantly higher than Rg1 group and Rb1 group (P0.05); there was no significant difference between Rg1 group and Rb1 group (P0.05) (2 people). Ginsenoside monomer Rg3, Rg1, 72h lymphocytes in peripheral blood of patients with nasopharyngeal carcinoma after Rb1, significantly increased the proportion of CD4+ lymphocyte subsets, CD4+/CD8+ ratio, and significantly reduced the proportion of CD8+, compared with Control group. The difference was statistically significant (P0.05), and a significant dose dependence; effect of Rg3 group was higher than that of Rg1 group and the Rb1 group (P0.05); there was no significant difference between Rg1 group and Rb1 group (P0.05). (3) ginsenoside Rg3, Rg1, 72h lymphocytes in peripheral blood of patients with nasopharyngeal carcinoma after Rb1 significantly increased peripheral blood T lymphocyte cell surface CD3+/HLA-DR+ and B cell surface expression of CD19+/CD69+. Compared with the Control group. The difference was statistically significant (P0.05), and showed a significant dose-dependent effect; Rg3 group was significantly higher than Rg1 group and Rb1 group (P0.05); the difference between the Rg1 group and Rb1 group had no statistical significance (P0.05). (4) ginsenoside Rg3, Rg1, Rb1 72h of peripheral blood lymphocytes in patients with nasopharyngeal carcinoma after radiotherapy treatment, can significantly promote peripheral blood lymphocyte Ig G, Ig M antibody secretion, compared with the Control group. The difference was statistically significant (P0.05), and showed a significant dose-dependent effect; Rg3 group was significantly higher than Rg1 group and Rb1 group (P0.05); no significant difference Rg1 group and Rb1 group (P0.05). (5) ginsenoside Rg3, Rg1, 72h lymphocytes in peripheral blood of patients with nasopharyngeal carcinoma after Rb1, IL-2 expression was significantly up-regulated in peripheral blood lymphocytes, and down-regulation of IL-6 expression, compared with the Control group the difference was statistically significant (P0.05), and a significant dose dependent; effect of Rg3 group was significantly higher than Rg1 group and Rb1 group (P0.05); there was no significant difference between Rg1 group and Rb1 group (P0.05). Conclusion: ginsenoside Rg3, Rg1, Rb1 can significantly enhance the radiotherapy of nasopharyngeal carcinoma patients with peripheral blood lymphocyte proliferation, antigen presentation to Correct, radiotherapy lymphocyte subsets imbalance and immune Th1/Th2 drift, improve the body of Ig G, Ig M antibody level was significantly better than that of Rg1 and Rg3 and Rb1. suggest that ginsenoside Rg3, Rg1, Rb1 can be used as immune enhancement caused by antagonistic potential of nasopharyngeal carcinoma radiotherapy agent immunosuppression.

【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R739.63

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 梅少林;袁紅艷;曹湘博;常雅萍;李平亞;劉金萍;;人參皂苷Rg3對(duì)HSE模型鼠的治療作用及免疫調(diào)節(jié)效應(yīng)[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2007年01期

2 張銳;徐華麗;于小風(fēng);曲紹春;陳明俠;睢大員;;20(S)-原人參二醇對(duì)荷瘤裸鼠化療的增效減毒作用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2009年02期

3 邱雪;洪鐵;孟勤;楊振;呂惠子;;人參皂苷單體Rb_1、Re及Rg_1對(duì)腎上腺素所致小鼠耳廓微循環(huán)障礙的改善作用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2009年02期

4 劉偉宏，龔守良，李新民，劉樹錚;人參三醇組甙對(duì)雄性大鼠免疫器官的輻射防護(hù)作用[J];白求恩醫(yī)科大學(xué)學(xué)報(bào);1994年01期

5 馬德慧;薛江東;姚春雨;孟憲龍;楊明霞;劉國(guó)文;;H5N2亞型禽流感病毒中藥佐劑滅活苗對(duì)公雛雞外周血T淋巴細(xì)胞亞群的影響[J];中國(guó)畜牧獸醫(yī);2009年09期

6 Marlinda Adham;Antonius N.Kurniawan;Arina Ika Muhtadi;Averdi Roezin;Bambang Hermani;Soehartati Gondhowiardjo;I Bing Tan;Jaap M.Middeldorp;;Nasopharyngeal carcinoma in Indonesia:epidemiology,incidence,signs,and symptoms at presentation[J];癌癥;2012年04期

7 史秀山;人參皂苷Rb1提高狂犬病疫苗免疫效果的研究[J];中國(guó)熱帶醫(yī)學(xué);2005年01期

8 毛平;馬駿;陳艷艷;虞桂珍;譚夢(mèng)暉;;不同藥性補(bǔ)氣中藥對(duì)小鼠脾淋巴細(xì)胞增殖及細(xì)胞因子分泌的影響[J];上海中醫(yī)藥大學(xué)學(xué)報(bào);2006年03期

9 陳曜;陳春山;;人參皂甙小分子的生物學(xué)作用[J];臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志;2010年21期

10 田志剛,劉杰,孫lm,李柏青,張捷,張建華;人參三醇型皂甙對(duì)IL-6基因的促轉(zhuǎn)錄效應(yīng)[J];中國(guó)藥理學(xué)通報(bào);1993年05期

相關(guān)博士學(xué)位論文 前1條

1 宋曉明;不同來(lái)源人參皂甙免疫佐劑作用的研究[D];浙江大學(xué);2009年

相關(guān)碩士學(xué)位論文 前1條

1 解慧梅;黃芪多糖、人參皂甙Rb1對(duì)豬口蹄疫疫苗的佐劑效果及相關(guān)機(jī)理研究[D];河北農(nóng)業(yè)大學(xué);2006年

，

本文編號(hào)：1767993